New Immunotherapy Prolongs Survival of Lung Cancer Patients
A combination of two immunotherapy drugs has significantly extended survival in patients with one of the deadliest forms of lung cancer, with trial data showing median survival nearly doubling against the current standard of care. Results from the Phase 3 study involving 563 patients were presented during a conference of the European Society for Medical Oncology in Madrid and also published simultaneously in the New England Journal of Medicine. Patients on the dual regimen had a median survival of 21.1 months, against 12.7 months for those given Imfinzi alone. The combination lowered mortality risk by 58% against the single-drug approach.…

